VolitionRx Limited (VNRX)
0.56
0.03 (6.06%)
At close: Mar 28, 2025, 3:59 PM
Company Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.
It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.
The company operates Nucleosomics a technology platform for blood test.
VolitionRx Limited is based in Austin, Texas.
VolitionRx Limited
| Country | United States |
| IPO Date | Mar 2, 2012 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Cameron Reynolds MBA |
Contact Details
Address: 13215 Bee Cave Parkway Austin, Texas United States | |
| Website | https://www.volition.com |
Stock Details
| Ticker Symbol | VNRX |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000093314 |
| CUSIP Number | 928661107 |
| ISIN Number | US9286611077 |
| Employer ID | 91-1949078 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Cameron Reynolds MBA | Founder, Chief Executive Officer, President & Director |
| Dr. Salvatore Thomas Butera DVM | Chief Executive Officer of Volition Veterinary Diagnostics Development LLC |
| Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
| Terig Hughes | Chief Financial Officer & Treasurer |
| Dr. Andrew Retter MBBS | Chief Medical Officer |
| Dr. Jacob Vincent Micallef MBA, Ph.D. | Chief Scientific Officer |
| Gael Forterre M.B.A. | Chief Commercial Officer |
| Louise Batchelor Day | Group Chief Marketing & Communications Officer |
| Nicholas Plummer | Group General Counsel |
| Sharon Ballesteros | U.S. Head of Quality & Development Process |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 4 | Filing |
| Mar 27, 2025 | 4 | Filing |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |
| Mar 04, 2025 | 4 | Filing |